NCT00113230 - Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions

Rectal Cancer

Interventions

DRUG

Avastin (Bevacizumab, RHUMAB VEGF)

Starting Dose 5 mg/kg intravenously on day one of radiotherapy, given every 2 weeks +/- 2 days for a total of 3 doses.

DRUG

Capecitabine

900 mg/m\^2 by mouth twice a day during days of radiation for all five weeks of therapy.

RADIATION

Radiation Therapy

45 Gy in 25 fractions to the pelvis followed by 5.4 Gy as a boost dose to the primary tumor with margin, for a total dose of 50.4 Gy over 28 treatment days.

Trial Locations (1)

77030

UT M. D. Anderson Cancer Center, Houston